Comparison of incidence of grades 3/4 common nonhematologic toxicities according to route of methotrexate administration
| . | Induction PO/IV, % . | P . | Consolidation PO/IV, % . | P . | IM-1 PO/IV, % . | P . | DI-1 PO/IV, % . | P . | IM-2 PO/IV, % . | P . | DI-2 PO/IV, % . | P . | Maint PO/IV, % . | P . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergic | 0.10/0 | .50 | 0/0 | — | 0.10/0.10 | 1.00 | 0.10/0.50 | .11 | 0/0 | — | 0.62/0.43 | .51 | 0/0 | — |
| Coagulation | 5.59/5.88 | .78 | 0.29/0.58 | .26 | 0.20/0 | .25 | 1.59/1.50 | .88 | 0/0 | — | 2.29/0.85 | .06 | 0.11/0 | .50 |
| Hepatic | 6.36/4.63 | .08 | 10.67/10.04 | .64 | 17.63/8.20 | < .0001 | 7.23/1.10 | < .0001 | 14.20/8.62 | .0001 | 7.48/2.78 | .001 | 8.40/10.00 | .23 |
| Infections | 7.62/9.06 | .23 | 7.08/7.05 | .98 | 4.11/5.14 | .27 | 10.60/8.32 | .08 | 6.29/3.08 | .0008 | 11.43/9.40 | .31 | 5.99/5.52 | .66 |
| Neurologic* | 3.28/4.53 | .14 | 3.39/3.57 | .83 | 2.15/3.26 | .12 | 1.39/2.51 | .07 | 1.22/1.54 | .54 | 2.49/1.50 | .27 | 0.74/0.94 | .63 |
| Seizures | 0.39/0.77 | .19 | 0.19/0.10 | .50 | 0.10/0.99 | .006 | 0.30/0.20 | .51 | 0/0.51 | .03 | 0.21/0.85 | .18 | 0/0 | — |
| Leuko | 0/0 | — | 0/0 | — | 0/0 | — | 0/0.20 | .25 | 0/0 | — | 0/0 | — | 0/0.10 | .50 |
| Pancreatitis | 0.39/0.10 | .19 | 0.19/0.10 | .50 | 0.10/0 | .50 | 0.59/0.20 | .15 | 0/0.10 | .50 | 0/0 | — | 0.11/0 | .50 |
| Renal | 0.19/0.39 | .34 | 0.10/0 | .50 | 0/0 | — | 0.20/0 | .25 | 0/0 | — | 0/0 | — | 0/0 | — |
| . | Induction PO/IV, % . | P . | Consolidation PO/IV, % . | P . | IM-1 PO/IV, % . | P . | DI-1 PO/IV, % . | P . | IM-2 PO/IV, % . | P . | DI-2 PO/IV, % . | P . | Maint PO/IV, % . | P . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergic | 0.10/0 | .50 | 0/0 | — | 0.10/0.10 | 1.00 | 0.10/0.50 | .11 | 0/0 | — | 0.62/0.43 | .51 | 0/0 | — |
| Coagulation | 5.59/5.88 | .78 | 0.29/0.58 | .26 | 0.20/0 | .25 | 1.59/1.50 | .88 | 0/0 | — | 2.29/0.85 | .06 | 0.11/0 | .50 |
| Hepatic | 6.36/4.63 | .08 | 10.67/10.04 | .64 | 17.63/8.20 | < .0001 | 7.23/1.10 | < .0001 | 14.20/8.62 | .0001 | 7.48/2.78 | .001 | 8.40/10.00 | .23 |
| Infections | 7.62/9.06 | .23 | 7.08/7.05 | .98 | 4.11/5.14 | .27 | 10.60/8.32 | .08 | 6.29/3.08 | .0008 | 11.43/9.40 | .31 | 5.99/5.52 | .66 |
| Neurologic* | 3.28/4.53 | .14 | 3.39/3.57 | .83 | 2.15/3.26 | .12 | 1.39/2.51 | .07 | 1.22/1.54 | .54 | 2.49/1.50 | .27 | 0.74/0.94 | .63 |
| Seizures | 0.39/0.77 | .19 | 0.19/0.10 | .50 | 0.10/0.99 | .006 | 0.30/0.20 | .51 | 0/0.51 | .03 | 0.21/0.85 | .18 | 0/0 | — |
| Leuko | 0/0 | — | 0/0 | — | 0/0 | — | 0/0.20 | .25 | 0/0 | — | 0/0 | — | 0/0.10 | .50 |
| Pancreatitis | 0.39/0.10 | .19 | 0.19/0.10 | .50 | 0.10/0 | .50 | 0.59/0.20 | .15 | 0/0.10 | .50 | 0/0 | — | 0.11/0 | .50 |
| Renal | 0.19/0.39 | .34 | 0.10/0 | .50 | 0/0 | — | 0.20/0 | .25 | 0/0 | — | 0/0 | — | 0/0 | — |
PO indicates oral; IM, interim maintenance phase; DI, delayed intensification phase; and Leuko, leukoencephalopathy.
Excluding seizures and leukoencephalopathy.